BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With the applications of LNPs rapidly expanding beyond vaccine
 s\, as well as beyond the liver\, it is of utmost importance to predict a
 nd minimize adverse reactions to guarantee patient safety in the clinic\,
  especially following a clinical hold on Verve Therapeutics' gene therapy
  earlier this year\, due to safety concerns surrounding the LNP delivery 
 system.\n\nReturning in December\, the 3rd LNP Immunogenicity and Toxicit
 y Summit will return as your unique forum uniting industry experts strivi
 ng to measure\, predict and monitor non-clinical and clinical safety risk
  for lipid nanoparticles to ensure regulatory compliance for vaccines\, g
 ene and cell therapies.\n\nJoin experts from Pfizer\, AstraZeneca\, Moder
 na\, BioNTech and Beam Therapeutics\, as they dive deep into mechanisms o
 f toxicity\, optimal delivery strategy\, PEG-lipid alternatives and in vi
 tro prediction\, to progress development of safer LNP-delivered therapeut
 ics.\n\nURLs:Website:&nbsp\;https://go.evvnt.com/2609743-0?pid=185Tickets
 :&nbsp\;https://go.evvnt.com/2609743-2?pid=185Brochure:&nbsp\;https://go.
 evvnt.com/2609743-3?pid=185\n\nPrices:Full Access Pass (Conference + Work
 shop Day) - Drug Developer Pricing: USD 4197.00\,Conference Only - Drug D
 eveloper Pricing: USD 2999.00\,Full Access Pass (Conference + Workshop Da
 y) - Academic Pricing: USD 3597.00\,Conference Only - Academic Pricing: U
 SD 2599.00\,Full Access Pass (Conference + Workshop Day) - Service Provid
 er Pricing: USD 5097.00\,Conference Only - Service Provider Pricing: USD 
 3699.00\n\nSpeakers:&nbsp\;Ana J Narvaez\, Director Translational Biology
 \, Moderna\, Bin Wu\, Founder and Chief Executive Officer\, Cytodigm\, Da
 niel Serna\, Principal Research Scientist\, Abbvie\, Dimitrios Bitounis\,
  Scientist\, Investigative Toxicology\, Sanofi\, Heinrich Haas\, Chief Te
 chnology Officer\, NeoVac\, Jason Pennucci\, Director\, Bioanalytical Sci
 ences\, Moderna\, Julien Couture-Senecal\, Co-Founder\, Azane Therapeutic
 s\, Kelly Colletti\, Director - Preclinical Bioanalytics\, Beam Therapeut
 ics\, Kevin Sun\, Assistant Professor\, Icahn School of Medicine at Mount
  Sinai\, Liping Zhou\, Senior Director\, Advanced Drug Delivery\, AstraZe
 neca\, Maja Sedic\, Senior Director\, Toxicology\, Orna Therapeutics\, Mo
 hammad Shadid\, Vice President\, Translational Sciences\, Korro Bio\, Nat
 alia Martin\, Orozco Chief Scientific Officer\, Providence Therapeutics\,
  Nina Neblung\, Non-clinical Safety Manager\, BioNTech SE\, Qi-Ying Hu\, 
 Chief Executive Officer\, Corti Therapeutics\, Randall Moreadith\, Chief 
 Development Officer\, Serina Therapeutics\, Sean Semple\, Vice President 
 - Preclinical Development\, Acuitas Therapeutics\, Smanla Tundup\, Direct
 or - Research and Development\, Eli Lilly and Co.\, Sophie Tourdot\, Asso
 ciate Research Fellow\, Immunogenicity Sciences Lead\, Pfizer\, Umberto C
 apasso Palmiero\, Senior Scientist\,Non - Viral Delivery\, Global Nucleic
  Acid Therapies\, Novo Nordisk\n\nCategory:&nbsp\;Conferences | Science\,
  Health and Medicine | Pharmaceuticals | Drug Development\n\nDate and Tim
 e:&nbsp\;9th December 2024 at 9:00 am to 11th December 2024 at 5:00 pm\n\
 nVenue details:&nbsp\;The Colonnade Boston\, 120 Huntington Avenue\, Bost
 on\, Massachusetts\, 02116\, United States\n
DTEND:20241211T170000
DTSTAMP:20260512T220334Z
DTSTART:20241209T090000
LOCATION:The Colonnade Boston\, 120\, Huntington Avenue\, Boston\, Massach
 usetts\, 02116\,
SEQUENCE:0
SUMMARY:With the applications of LNPs rapidly expanding beyond vaccines\, 
 as well as beyond the liver\, it is of utmost importance to predict and m
 inimize ad...
UID:97defe2d-158f-432d-ae6c-a6aa10cce037
END:VEVENT
END:VCALENDAR